Celyad Oncology SA (EBR:CYAD)

Celyad Oncology Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jul 18, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	14	29	16	11	79	92
Market Cap Growth	82.56%	82.56%	41.33%	-85.61%	-13.96%	-31.75%
Enterprise Value	11	24	12	-1	76	69
Last Close Price	0.35	0.71	0.39	0.51	3.52	6.62
PS Ratio	77.73	158.59	158.40	-	-	18459.66
PB Ratio	28.29	57.72	2.56	2.65	1.82	2.98
P/TBV Ratio	29.63	60.45	2.58	2.96	10.00	-
EV/Sales Ratio	60.02	130.42	114.87	-	-	13862.06
Debt / Equity Ratio	1.77	1.77	0.17	0.06	0.06	0.12
Asset Turnover	0.01	0.01	0.01	-	-	0
Quick Ratio	1.79	1.79	3.34	1.31	2.34	1.53
Current Ratio	2.29	2.29	3.79	1.42	2.48	1.67
Return on Equity (ROE)	-170.92%	-170.92%	-159.08%	-170.72%	-71.05%	-44.91%
Return on Assets (ROA)	-27.99%	-27.99%	-33.14%	-31.92%	-23.32%	-21.04%
Return on Capital (ROIC)	-83.59%	-83.59%	-99.97%	-62.57%	-42.08%	-38.76%
Earnings Yield	-40.28%	-19.74%	-52.29%	-358.06%	-33.38%	-18.64%
FCF Yield	-	-19.26%	-99.65%	-246.08%	-33.97%	-30.14%
Buyback Yield / Dilution	-61.06%	-61.06%	-13.84%	-44.80%	-11.92%	-11.33%

Updated Sep 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.